Breast Cancer Survivors With Obesity - Semaglutide's Impact on Preclinical Markers of Cardiovascular Disease
Mayo Clinic
Summary
This phase IV trial studies whether adding semaglutide to structured lifestyle support improves heart and blood vessel health in postmenopausal obese breast cancer survivors (BCS) who are taking an aromatase inhibitor. In postmenopausal BCS who are taking an aromatase inhibitor, obesity raises the risk of heart and blood vessel problems. Semaglutide is a medicine approved by the United States Food and Drug Administration for weight loss and for lowering the risk of heart events in people with heart disease. The structured lifestyle support in this trial includes counseling on nutrition and physical activity which provides specific recommendations for individuals to follow.
Eligibility
- Age range
- 46–55 years
- Sex
- Female
- Healthy volunteers
- No
Inclusion Criteria: * Breast cancer diagnosed after menopause (menopause defined as the natural/spontaneous cessation of menses for at least 12 months) * Breast cancer (BC) diagnosed within the past five years * BC stage 1, 2, or 3 * Aged 46-55 years * Body mass index (BMI) ≥ 30 kg/m\^² * Current use of an aromatase inhibitor * Ability to participate in all portions of the study, including willingness to self-inject Exclusion Criteria: * \> 5% change in weight during the 3 months prior to screening and/or weight fluctuation of ≥ 20 pounds within the past 6 months (self-report) * Early menop…
Interventions
- ProcedureBiospecimen Collection
Undergo blood sample collection
- ProcedureDual X-ray Absorptiometry
Undergo DEXA
- OtherFunctional Assessment
Undergo vascular function testing
- BehavioralLifestyle Counseling
Receive structured lifestyle intervention recommendations
- DrugSemaglutide
Given SC
Location
- Mayo Clinic in FloridaJacksonville, Florida